Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · IEX Real-Time Price · USD
1,044.66
-12.36 (-1.17%)
At close: Jul 2, 2024, 4:00 PM
1,045.10
+0.44 (0.04%)
After-hours: Jul 2, 2024, 7:25 PM EDT
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $13.10B in the twelve months ending March 31, 2024, with 5.90% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $3.15B, a -0.54% decrease year-over-year. In the year 2023, Regeneron Pharmaceuticals had annual revenue of $13.12B with 7.76% growth.
Revenue (ttm)
$13.10B
Revenue Growth
+5.90%
P/S Ratio
8.64
Revenue / Employee
$973,985
Employees
13,450
Market Cap
113.21B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
Dec 31, 2019 | 6.56B | 1.41B | 27.44% |
Dec 31, 2018 | 5.15B | -726.60M | -12.37% |
Dec 31, 2017 | 5.87B | 1.01B | 20.82% |
Dec 31, 2016 | 4.86B | 756.67M | 18.44% |
Dec 31, 2015 | 4.10B | 1.28B | 45.55% |
Dec 31, 2014 | 2.82B | 714.81M | 33.96% |
Dec 31, 2013 | 2.10B | 726.27M | 52.69% |
Dec 31, 2012 | 1.38B | 932.65M | 209.20% |
Dec 31, 2011 | 445.82M | -13.25M | -2.89% |
Dec 31, 2010 | 459.07M | 79.81M | 21.04% |
Dec 31, 2009 | 379.27M | 140.81M | 59.05% |
Dec 31, 2008 | 238.46M | 113.43M | 90.73% |
Dec 31, 2007 | 125.02M | 61.58M | 97.05% |
Dec 31, 2006 | 63.45M | -2.75M | -4.15% |
Dec 31, 2005 | 66.19M | -107.82M | -61.96% |
Dec 31, 2004 | 174.02M | 116.52M | 202.65% |
Dec 31, 2003 | 57.50M | 35.51M | 161.49% |
Dec 31, 2002 | 21.99M | 15.00K | 0.07% |
Dec 31, 2001 | 21.97M | -37.30M | -62.93% |
Dec 31, 2000 | 59.28M | 24.78M | 71.82% |
Dec 31, 1999 | 34.50M | -3.83M | -9.99% |
Dec 31, 1998 | 38.33M | 5.23M | 15.79% |
Dec 31, 1997 | 33.10M | 8.99M | 37.26% |
Dec 31, 1996 | 24.11M | -3.27M | -11.94% |
Dec 31, 1995 | 27.38M | 4.19M | 18.08% |
Dec 31, 1994 | 23.19M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cigna | 206.00B |
Elevance Health | 171.75B |
HCA Healthcare | 66.72B |
Sanofi | 51.60B |
Medtronic | 32.36B |
Gilead Sciences | 27.45B |
Stryker | 20.96B |
Boston Scientific | 14.71B |
REGN News
- 21 minutes ago - Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD - GlobeNewsWire
- 21 minutes ago - Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD - GlobeNewsWire
- 11 hours ago - The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Invites Impacted Investors To Reach Out - Accesswire
- 12 hours ago - Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm - PRNewsWire
- 15 hours ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN - PRNewsWire
- 2 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN - GlobeNewsWire
- 4 days ago - The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Make Contact - Accesswire
- 4 days ago - Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma - GlobeNewsWire